1. Pink Sheet
  2. >>Market Access

Medicare Unveils Negotiated Prices, But Near-Term Opportunity To Learn From Process Is Limited

 
• By Cathy Kelly

Some manufacturers may have the dubious distinction of being targeted in the first and second rounds of the negotiation program, but at least will be familiar with the process the next time.

So Far Opportunities For Learning Have Been Limited. • Source: Shutterstock

The US Centers for Medicare and Medicaid Services did not describe how it arrived at Medicare negotiated prices for the first 10 Part D drugs to go through the process in its 15 August announcement, which likely means that at least some manufacturers in the second round will not have the benefit of experience to help navigate the process.

Key Takeaways

  • Stakeholders hoping to learn from the initial round of Medicare price negotiations may have to wait until March for insight into the agency’s approach because the price announcement was not very informative.

  • CMS will release a narrative about its processes by 1 March as required by law, but will not share its description with participating manufacturers in advance

CMS will announce the next group of drugs targeted for negotiation on 1 February 2025, but it is not required to provide a description of the process it used in the first round of negotiations until

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Pink Sheet for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from Market Access

Managed Access Agreement Fails To Help BioMarin’s Brineura Secure Routine Reimbursement In England

 
• By Francesca Bruce

BioMarin’s ultra-rare disease drug Brineura has breached cost-effectiveness thresholds for highly specialized treatments in England and looks set to be denied routine funding on the National Health Service.

Industry Leaders Grapple With Trump’s Most Favored Nation Pricing Plan

 
• By Jessica Merrill

At the Bank of America health care conference, pharma leaders speculated on the impact of Trump’s most favored nation pricing executive order on US and European markets.

Most Favored Nation Policy ‘Lazy, Misguided,’ But US Price Reforms Politically ‘Inevitable’

 
• By Cathy Kelly

Policy experts and pharma executives react to President Trump’s executive order on “equalizing” drug prices between the US and comparable nations at the ISPOR 2025 conference.

EU HTA Regulation: How Rare Disease Drug Makers Can Meet Worrisome JCAs Data Requirements

 
• By Francesca Bruce

In an interview with the Pink Sheet, Fonadazione Telethon’s Stefano Benvenuti discusses how companies developing and marketing rare disease treatments can overcome the challenges presented by EU-joint clinical assessment evidence requirements.

More from Pink Sheet

HHS Secretary Kennedy Says Trump Will Make Final Decision On Mifepristone Policy

 
• By Derrick Gingery

With an FDA review ongoing, Kennedy’s admission, made during a Senate hearing on the Health and Human Services Department’s budget request, suggests political officials could supersede scientific decisions.

Industry Leaders Grapple With Trump’s Most Favored Nation Pricing Plan

 
• By Jessica Merrill

At the Bank of America health care conference, pharma leaders speculated on the impact of Trump’s most favored nation pricing executive order on US and European markets.

Most Favored Nation Policy ‘Lazy, Misguided,’ But US Price Reforms Politically ‘Inevitable’

 
• By Cathy Kelly

Policy experts and pharma executives react to President Trump’s executive order on “equalizing” drug prices between the US and comparable nations at the ISPOR 2025 conference.